Centessa Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Centessa Pharmaceuticals's earnings have been declining at an average annual rate of -9.3%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 171.8% per year.
Key information
-9.3%
Earnings growth rate
22.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 171.8% |
| Return on equity | -64.0% |
| Net Margin | -2,204.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Health Check: How Prudently Does Centessa Pharmaceuticals (NASDAQ:CNTA) Use Debt?
Mar 07
Centessa Pharmaceuticals snaps multi-day losing streak; up 10%
Oct 20Centessa hemophilia B therapy SerpinPC gets FDA orphan drug status
Sep 14Centessa Pharmaceuticals GAAP EPS of -$0.69
Aug 10Checking In On Centessa Pharmaceuticals
Dec 23Centessa Pharmaceuticals stock pops 20%+ intraday to post-IPO high
Jun 14Revenue & Expenses BreakdownBeta
How Centessa Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 7 | -151 | 54 | 124 |
| 30 Sep 23 | 0 | -157 | 55 | 120 |
| 30 Jun 23 | 0 | -173 | 55 | 128 |
| 31 Mar 23 | 0 | -212 | 57 | 148 |
| 31 Dec 22 | 0 | -216 | 55 | 155 |
| 30 Sep 22 | 0 | -234 | 54 | 169 |
| 30 Jun 22 | 0 | -220 | 55 | 158 |
| 31 Mar 22 | 0 | -197 | 52 | 122 |
| 31 Dec 21 | 0 | -381 | 43 | 96 |
| 30 Sep 21 | 0 | -324 | 30 | 57 |
| 30 Jun 21 | 0 | -286 | 18 | 34 |
| 31 Mar 21 | 0 | -246 | 6 | 17 |
| 31 Dec 20 | 0 | -11 | 1 | 9 |
Quality Earnings: CNTA is currently unprofitable.
Growing Profit Margin: CNTA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CNTA is unprofitable, and losses have increased over the past 5 years at a rate of 9.3% per year.
Accelerating Growth: Unable to compare CNTA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CNTA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: CNTA has a negative Return on Equity (-63.95%), as it is currently unprofitable.